Miriplatin (hydrate)

TargetMol
Product Code: TAR-T21297
Supplier: TargetMol
CodeSizePrice
TAR-T21297-1mg1mg£106.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T21297-5mg5mg£149.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T21297-10mg10mg£173.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T21297-25mg25mg£269.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T21297-50mg50mg£374.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T21297-100mg100mg£511.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Miriplatin (MPT) is a novel platinum complex used in TACE that shows promise for the treatment of hepatocellular carcinoma (HCC). Miriplatin is a lipophilic platinum complex that can be easily suspended in Lipiodol and gradually releases active platinum compounds in tumor tissue.
CAS:
250159-48-9
Formula:
C34H70N2O5Pt
Molecular Weight:
782.027
Pathway:
DNA Damage/DNA Repair
Purity:
0.98
SMILES:
O.CCCCCCCCCCCCCC(=O)O[Pt--]1([NH2+][C@@H]2CCCC[C@H]2[NH2+]1)OC(=O)CCCCCCCCCCCCC
Target:
DNA Alkylation

References

1. Yasui D, Murata S, Onozawa S, Mine T, Ueda T, Sugihara F, Kawamoto C, Uchida E, Kumita S. Improved efficacy of transcatheter arterial chemoembolization using warmed miriplatin for hepatocellular carcinoma. Biomed Res Int. 2014;2014:359296. doi: 10.1155/2014/359296. Epub 2014 Sep 8. PubMed PMID: 25276780; PubMed Central PMCID: PMC4172877. 2. Arai H, Abe T, Takayama H, Toyoda M, Ueno T, Kakizaki S, Sato K. Safety and efficacy of balloon-occluded transcatheter arterial chemoembolization using miriplatin for hepatocellular carcinoma. Hepatol Res. 2014 Aug 8. doi: 10.1111/hepr.12403. [Epub ahead of print] PubMed PMID: 25132539. 3. Ishikawa T, Abe S, Inoue R, Sugano T, Watanabe Y, Iwanaga A, Seki K, Honma T, Nemoto T, Takeda K, Yoshida T. Predictive factor of local recurrence after balloon-occluded TACE with miriplatin (MPT) in hepatocellular carcinoma. PLoS One. 2014 Jul 21;9(7):e103009. doi: 10.1371/journal.pone.0103009. eCollection 2014. PubMed PMID: 25047920; PubMed Central PMCID: PMC4105420. 4. Ito T, Okubo H, Kokubu S, Miyazaki A, Ando H, Fujimura A, Watanabe S. Radiofrequency ablation combined with chemolipiodolization in a porcine liver: Comparison of the pharmacokinetic analysis with cisplatin powder and miriplatin. Hepatol Res. 2014 Jul 7. doi: 10.1111/hepr.12387. [Epub ahead of print] PubMed PMID: 25040841.